In T-ALL, supraphysiological MYB activity can be induced through translocations, tandem duplications, and genetic variants conferring increased protein stability; however, most T-ALL tumors (~83%–95%) have no known MYB genetic lesion (57–63, 83). The gene discussed is MYB; the disease is acute lymphoblastic leukemia.